Like Wile E. Coyote grasping an anvil and waiting for the ever-elusive roadrunner, biotech startups must have a sinking feeling while standing on the edge of the fiscal cliff.
The federal budget “fix” — if it actually happens — would automatically slash the National Institutes of Health budget, which supports basic research that often underpins commercial drugs, diagnostics and devices, and presumably obliterate funding for Small Business Innovation Research grants. Those SBIR funds often are tapped by incubating life sciences companies as a bridge to proof-of-concept stage and venture capital funding.
Beta. Initial Form 1-A only. Target raise is the stated Amount to be Raised, totaled. Compared with the same dates one year earlier.
YTD: Jan 1, 2026 - Oct 26, 2026 vs Jan 1, 2025 - Oct 26, 2025
Share this graph
Number of Filings131Prior 126 +4.0%
Target Raise, Total$3.40BPrior $3.54B -3.9%
This YTD
Year prior
Change
Filings
131
126
+4.0%
Target raise
$3.40B
$3.54B
-3.9%
Sponsored by
the Crowded Media Group
the leading digital news service covering the global Fintech Industry, including digital assets, crowdfunding, tokenization, and other innovations in capital markets. email us@CrowdfundInside
This display counts initial Form 1-A filings only. It does not represent subsequent filings, including Form 1-A/A amendments or Form 1-A POS post-qualification updates filed by the issuer. Amounts are the stated Amount to be Raised on the initial filing, not capital raised and not amounts revised in later filings.
Crowdfund Insider is the leading news website covering the emerging global industry of disruptive finance including investment crowdfunding, Blockchain, online lending, and other forms of Fintech.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it and agree to our terms of service.